Enhancing [¹⁷⁷Lu]Lu-DOTA-TATE therapeutic efficacy in vitro by combining it with metronomic chemotherapeutics.

ABSTRACT:

Background

Peptide receptor radionuclide therapy (PRRT) uses [¹⁷⁷Lu]Lu-[DOTA⁰-Tyr³]octreotate ([¹⁷⁷Lu]Lu-DOTA-TATE) to treat patients with neuroendocrine tumours (NETs) overexpressing the somatostatin receptor 2A (SSTR2A). It has shown significant short-term improvements in survival and symptom alleviation, but there remains room for improvement. Here, we investigated whether combining [¹⁷⁷Lu]Lu-DOTA-TATE with chemotherapeutics enhanced the in vitro therapeutic efficacy of [¹⁷⁷Lu]Lu-DOTA-TATE.

Results

Transfected human osteosarcoma (U2OS + SSTR2A, high SSTR2A expression) and pancreatic NET (BON1 + STTR2A, medium SSTR2A expression) cells were subjected to hydroxyurea, gemcitabine or triapine for 24 h at 37

SUBMITTER: Cheng J 

PROVIDER: S-EPMC11322472 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature